This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Should You Buy It: AmerisourceBergen

AmerisourceBergen (ABC - Get Report) is often overlooked as the middle-man in the pharmaceutical industry. The company is one of the largest drug wholesalers in North America, which is a business that carries razor- thin gross margins of only 4%. But what Amerisource lacks in profitability, it makes up for in volume, posting north of $66 billion of revenue last year.

The stock was upgraded Wednesday from Neutral to Buy at Merrill Lynch. The analyst cited the company's low valuation and solid price increases in branded drug pricing for the call. Still, Wall Street has a relatively cool outlook for the shares, with just four out of 13 analysts surveyed by Bloomberg rating AmerisourceBergen a Buy.

At Wednesday's closing price of $38.53, the stock is trading at 12 times expected fiscal 2009 (ending September) earnings of $3.21 This represents a 28% discount to the company's historical average valuation over the past decade, and marks the lowest multiple the stock has received in three years. With that in mind, I'm here to answer readers' questions: Should you buy it? Does AmerisourceBergen have the cure for investors' woes in this volatile environment?

The Right Active Ingredients

The company posted better-than-expected third-quarter results July 24. AmerisourceBergen earned 73 cents a share, which was 7 cents ahead of the consensus analyst estimate. Revenue grew 14.5% year-over-year to $17.51 billion, coming up $120 million less than expected. Still, management is expecting its third straight annual double-digit earnings gain in fiscal 2009.

In addition to improved industry pricing, AmerisourceBergen is achieving this growth by cutting costs. The company is also in the process of selling its workers' compensation division (PMSI), which had been a drag on earnings.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABC $85.10 0.00%
CAH $78.46 0.00%
CVS $100.50 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs